Cell Lines for Drug Discovery: Elevating Target-Protein Levels Using Engineered Transcription Factors
Open Access
- 1 February 2004
- journal article
- Published by Elsevier BV in SLAS Discovery
- Vol. 9 (1), 44-51
- https://doi.org/10.1177/1087057103260115
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Activation of Vascular Endothelial Growth Factor A Transcription in Tumorigenic Glioblastoma Cell Lines by an Enhancer with Cell Type-specific DNase I AccessibilityPublished by Elsevier BV ,2002
- Engineering polydactyl zinc-finger transcription factorsNature Biotechnology, 2002
- Patent status of the therapeutically important G-protein-coupled receptorsExpert Opinion on Therapeutic Patents, 2001
- Synthetic Zinc Finger Transcription Factor Action at an Endogenous Chromosomal SiteJournal of Biological Chemistry, 2000
- Structure and Developmental Expression of the Mouse CCK-B Receptor GeneBiochemical and Biophysical Research Communications, 2000
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Cholecystokinin receptorsCellular and Molecular Neurobiology, 1995
- The crystal structure of a two zinc-finger peptide reveals an extension to the rules for zinc-finger/DNA recognitionNature, 1993
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970